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estimated average HIV incidence rate among pregnant and breast-feeding women was
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IntroductionHIV acquisition among pregnant and breast-feeding
women increases risk of maternal morbidity and
mortality, and accounts for a significant, and growing,
proportion of pediatric HIV infections globally [1]. A
meta-analysis of 19 studies conducted between 1980
and 2012 estimated an average HIV incidence rate of 3.8/
100 person-years [95% confidence interval (CI): 3.0–4.6]
among pregnant and breast-feeding women in sub-
Saharan Africa (SSA) [2]. Although this estimate is above
the World Health Organization’s (WHO) threshold for
substantial risk of HIVacquisition [3], the rapidly evolving
HIV prevention and treatment landscape since publica-
tion of this review may have important implications for
maternal HIV incidence.
In 2013, the WHO updated HIV treatment guidelines,
expanding antiretroviral therapy (ART) eligibility to
CD4þ  500 cells/ml [4], and in 2015, it recommended
universal treatment for HIV [5]. These changes, together
with increased uptake of HIV testing and counseling and
medical male circumcision [6–8], coincided with a 30%
decline in the estimated number of new adult HIV
infections in SSA between 2010 and 2017 [9]. Similar
temporal trends in HIV incidence have been observed in
three population-based cohort studies in SSA [10–12],
with more gradual declines observed among women
than among men [11,12]. Although combination HIV
prevention and treatment interventions may not directly
target pregnant and breast-feeding women, these
populations may experience downstream benefits in
HIV prevention. In at least one study [13], maternal HIV
incidence was considerably lower in a cohort of pregnant
and breast-feeding women participating in a community-
basedHIV prevention program than estimates of maternal
incidence from the previous review [2].
Although the previous review observed evidence of
heterogeneity among study-specific estimates of the
incidence rate and the association between pregnancy and
risk of HIV acquisition, their investigation into the
underlying factors contributing to this variability was
limited [2]. A better understanding of features contribut-
ing to variation in estimates is critical for guiding future
research and policy, and for developing efficient strategies
to reduce horizontal and vertical HIV transmission
during pregnancy and breast-feeding.
In this updated review of literature from SSA between
1980 and 2018, we sought to summarize estimates of HIV
incidence among pregnant and breast-feeding women;
summarize estimates of the associations between preg-
nancy and risk of maternal HIV acquisition and between
breast-feeding and risk of HIV acquisition; and identify
population and methodological characteristics contribut-
ing to variation in study-specific estimates of incidence
and association.Methods
This review is registered with PROSPERO
(CRD42017079577) and follows the Preferred Report-
ing Items for Systematic Reviews and Meta-Analysis
Guidelines [14].
Study selection and data abstraction
We searched PubMed, Embase, PsycInfo, and the
Cochrane Library for relevant literature published
between 1 January 1980 and 1 December 2018
(Table S1, http://links.lww.com/QAD/B657). We also
searched online abstract archives from HIV Research for
Prevention Conference (2014–2018), Conference of
Retroviruses and Opportunistic Infections (2014–2018),
and International AIDS Society Conferences (2001–
2018) using the terms (‘pregnant’, ‘pregnancy’, or
‘postpartum’) and (‘incident’, ‘incidence’, or ‘serocon-
vert’).
We screened resulting titles and abstracts to identify
publications that referred to HIV incidence among
women or to pregnancy/breast-feeding and HIV. We
conducted a full text review of included publications to
identify primary research reports with estimates of (or
sufficient information to derive) the incidence rate of
HIV among pregnant and breast-feeding women, the
incidence rate ratio (IRR) or hazard ratio contrasting
HIV incidence between pregnant and nonpregnant
periods, and/or the IRR or hazard ratio contrasting
HIV incidence between breast-feeding and non-breast-
feeding periods. Included studies were restricted to those
published in English and conducted in SSA.We requested
additional information from authors when publications
contained relevant but insufficient information, and
reviewed the bibliographies of included publications for
relevant references.
Two investigators reviewed each publication at screening
and full-text review; disagreements were resolved by
consensus. Data on outcomes and exposures of interest
and key population and methodological features of each
study were abstracted into standardized tables by one
reviewer and checked by two others. When more than
one publication reported the same outcome from the
same study population over the same period, we included
the report considered most complete.
Outcome and exposure definitions
HIV incidence, the primary outcome, was defined as the
number of new HIV infections per 100 person-years.
Pregnancy and breast-feeding represented periods of
interest in studies contributing incidence rate estimates,
and represented exposures of interest in studies estimating
the IRR or hazard ratio. We accepted all definitions in
our primary analyses. In a sensitivity analysis, we excluded
studies where the breast-feeding period exceeded 24
months postpartum [15].
Statistical approach
We used inverse-variance-weighted random-effects
meta-analysis to estimate natural log-transformed mea-
sures of the average HIV incidence rate among pregnant
and breast-feeding women, the average association
between pregnancy and risk of HIV acquisition, the
average association between breast-feeding and risk of
HIV acquisition, and 95% prediction intervals around
summary estimates. The 95% prediction intervals convey
the estimated spread of the random-effects distribution,
and can be informally interpreted as 95% CI for the true
rate or association to be estimated in a randomly selected
study population [16–18]. When zero seroconversions
were reported, we applied a half-integer continuity
correction to prevent the estimate from being omitted. As
IRRs roughly approximate hazard ratios [19], we pooled
these estimates for meta-analysis and assumed approxi-
mate collapsibility since HIV acquisition is rare [20].
Summary estimates and 95% prediction intervals were
exponentiated for interpretability.
Because of the potential for publication bias, we drew
funnel plots and analyzed them with the symmetry test of
Egger et al. and with Duval and Tweedie’s trim-and-fill
imputation method [21,22]. We analyzed overall hetero-
geneity using 95% prediction intervals and the P value for
Cochrane’s Q statistic. We used stratified analyses and
univariate random-effects meta-regression to analyze
heterogeneity further by comparing average rates and
associations by population characteristics of included
studies. Meta-regression was also used to explore associa-
tions between estimates andmethodological aspects related
to study quality [23,24]. When a single study contributed
information to more than one stratum of a variable, we
used robust variances to account for correlation [25].Given
the large number of studies contributing estimates of the
incidence rate, we also constructed separate multivariable
models for each potential source of heterogeneity of the
incidence rate. Each model adjusted for region, years of
study implementation, and calendar time to account for
differences in HIV prevalence and ART coverage. All
analyses were conducted using the Metafor package in R,
version 3.5.1 (R Foundation for Statistical Computing,
Vienna, Austria) [26].
Sources of heterogeneity
Characteristics related to underlying HIV risk – region,
calendar time, age, membership of a high-risk popula-
tion, and participant enrollment in an HIV-prevention
clinical trial – may be associated with estimates of
incidence and association. As studies contributing
estimates of the association had limited variability in
calendar time, and did not provide age-stratified results,
these features were only evaluated as sources of
heterogeneity of the incidence rate.
We defined region using the World Bank’s classifications,
and calendar time based on mid-year of studyimplementation. We examined calendar time continu-
ously, as a quadratic function, and categorically with three
periods: precombination HIV prevention (before 2010),
early adoption (2010–2014), and program expansion
(after 2014). These periods correspond to important
updates to WHO HIV treatment and prevention
recommendations [4,5,27,28], and their implementation
across SSA [6–8]. We defined age groups based on the
most commonly reported categorization in the literature:
less than 20, 20–24, 25–29, and at least 30. Other age
group categorizations were considered in sensitivity
analyses. We used a binary variable to distinguish between
studies that enrolled a ‘high-risk’ cohort (e.g. HIV-
discordant couples or female sex workers) and those that
did not. We stratified by type of ‘high-risk’ group in
sensitivity analyses. Studies were also classified according
to whether participants were enrolled in a clinical trial
evaluating an HIV prevention intervention.
The following features related to the measurement of
incident infections and person-time may also be
associated with estimates of incidence and association:
study design, use of results from repeat HIV testing to
identify seroconversions, reproductive periods observed
over follow-up, use of HIV DNA/RNA PCR in the
HIV-testing algorithm, and method for estimating date of
HIV infection. As all studies contributing estimates of the
association used repeat HIV testing and observed all
reproductive periods over follow-up, these features were
only evaluated as sources of heterogeneity of the
incidence rate.
Finally, estimates of the IRR or hazard ratio may be
related to the inclusion of breast-feeding-exposed periods
in the reference group, adjustment for confounders, and
adjustment for time-varying measures of condom use and
intercourse frequency.Results
Our search yielded 5186 nonduplicate abstracts (Fig. 1).
Screening resulted in 202 publications for full-text
review, of which 57 met inclusion criteria. After
excluding 20 publications because of overlapping cohorts
and outcomes, 37 publications remained (Table 1).
Thirty-four contributed estimates of the HIV incidence
rate [13,29–61], and 10 contributed estimates of
either the IRR or hazard ratio [55–64]. Follow-up
ranged from 45 person-years to 57 240 person-years.
Most studies were conducted in southern Africa (n¼ 20)
[13,29,30,32,34,35,39–44,48,51,52,54,55,60,61,64]. The
mid-point of follow-up occurred before 2010 in 26 studies
[29,32,34–36,38–44,48,50,52–64], between 2010 and
2014 in eight [30,31,33,37,46,47,49,55], and after 2014
in three [13,45,51]. Two studies reported results stratified
by calendar time [55,56]. In seven studies, participants
6672 references identified 
• 6253 through database search
• 407 through conference search
• 12 through reference list search
5186 abstracts screened 
1486 duplicates removed
202 publications reviewed
57 publications met inclusion 
criteria
37 publications provided 
estimates for analyses
4984 abstracts excluded
20 publications excluded due to 
duplicative cohorts 
• 13 conference abstracts
• 7 peer-reviewed publications
145 publications excluded 
• 2 not found
• 1 not conducted in sub-Saharan Africa
• 1 not in English
• 26 not primary research
• 19 no measure of HIV incidence
• 48 no measure of HIV incidence during
pregnancy or breast-feeding 
• 48 only measured cumulative incidence of
HIV during pregnancy and/or breast-feeding
Fig. 1. Study selection flowchart.were enrolled in an HIV prevention trial [32,43,54,60–
62,64]. Four studies enrolled high-risk study populations
[54,57,62,63], and two studies reported results stratified
by risk-group [58,59]. Eight studies reported estimates of
incidence stratified by age [13,30,38,39,44,48,55,58].
There was limited variability in how studies measured
incidence after accounting for study design (Table S2,
http://links.lww.com/QAD/B658). Prospective cohort
studies (n¼ 24) enrolled HIV-seronegative women and
retested them over follow-up to identify changes in HIV
serostatus. Twenty-one prospective cohort studies con-
tributed estimates of the incidence rate among pregnant
and breast-feeding women [13,29,30,32,37–40,42–
44,48–50,52,54,58–61], and eight contributed estimates
of the IRR or hazard ratio [57–64]. Eleven cross-
sectional studies contributed estimates of the incidence
rate among pregnant and breast-feeding women [31,33–
36,41,45–47,51,53]. In these studies, HIV status at the
time of the first antenatal visit was retrospectively assessed
at the time of enrollment, which occurred in the third
trimester [31,41,46,47], at delivery [33–35,51], or in the
postpartum period [36,45,53]. Women classified as HIV-
negative in pregnancy were enrolled and current HIVserostatus was assessed to identify new HIV infections.
Finally, two studies nested within large population-based
surveillance studies contributed estimates of both the
incidence rate and the hazard ratio [55,56]. These studies
used prospectively collected data from HIV surveillance
assessments to assess changes in serostatus over time.
HIV incidence during pregnancy and
breast-feeding
Studies contributing estimates of incidence during
pregnancy typically captured the period between the
first antenatal visit and delivery, while studies contribut-
ing estimates of incidence during breast-feeding captured
the period from delivery up to 24 months postpartum
depending on length of follow-up (Table 1).
Thirty-four studies contributed 100 758 person-years of
follow-up and generated 44 estimates of HIV incidence
among pregnant and/or breast-feeding women. Ten
studies reported stratified estimates of incidence during
pregnancy and during breast-feeding [13,37,39,44,54–
59]. Using all available estimates, we observed little
difference in the average HIV incidence rate during
pregnancy only (n¼ 22, 3.4/100 person-years, 95%
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co
h
o
rt
1
9
8
8
–1
9
9
2
1
7
3
9
0
-
D
at
e
o
f
d
el
iv
er
y
to
2
4
m
o
n
th
s
p
o
st
p
ar
tu
m
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
3
2
m
o
n
th
s,
b
u
t
st
ra
ti
fi
ed
an
al
ys
es
en
ab
le
d
th
e
re
st
ri
ct
io
n
o
f
es
ti
m
at
es
to
2
4
m
o
n
th
s
p
o
st
p
ar
tu
m
-
-
N
o
N
o
M
io
tt
i
et
al
.
[4
0
]
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
1
9
8
9
–1
9
9
3
4
3
9
8
8
-
D
at
e
o
f
d
el
iv
er
y
to
2
4
m
o
n
th
s
p
o
st
p
ar
tu
m
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
n
o
t
p
ro
vi
d
ed
-
-
N
o
N
o
V
an
d
e
P
er
re
et
al
.
[5
0
]
Ea
st
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
1
9
9
8
–1
9
9
0
1
8
4
7
4
-
D
at
e
o
f
d
el
iv
er
y
to
2
4
m
o
n
th
s
p
o
st
p
ar
tu
m
.
Fo
ll
o
w
-u
p
co
n
ti
n
u
ed
to
3
6
m
o
n
th
s
p
o
st
p
ar
tu
m
,
b
u
t
st
ra
ti
fi
ed
es
ti
m
at
es
en
ab
le
d
as
ce
rt
ai
n
m
en
t
o
f
in
ci
d
en
ce
b
et
w
ee
n
d
el
iv
er
y
an
d
2
4
m
o
n
th
s
o
n
ly
-
-
N
o
N
o
St
u
d
ie
s
th
at
co
n
tr
ib
u
te
d
es
ti
m
at
es
o
f
th
e
in
ci
d
en
ce
ra
te
d
u
ri
n
g
p
re
gn
an
cy
an
d
b
re
as
t-
fe
ed
in
g
Fa
tt
i
et
al
.
[1
3
]
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
2
0
1
3
–2
0
1
6
1
1
8
2
8
D
at
e
o
f
fi
rs
t
A
N
C
vi
si
t
to
d
at
e
o
f
d
el
iv
er
y.
M
ed
ia
n
ge
st
at
io
n
al
ag
e
at
fi
rs
t
A
N
C
w
as
1
6
w
ee
ks
D
at
e
o
f
d
el
iv
er
y
to
1
8
m
o
n
th
s
p
o
st
p
ar
tu
m
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
n
o
t
p
ro
vi
d
ed
.
El
ev
en
p
er
ce
n
to
fw
o
m
en
w
er
e
lo
st
to
fo
ll
o
w
-u
p
b
y
1
2
m
o
n
th
s
p
o
st
p
ar
tu
m
-
-
N
o
N
o
Jo
h
n
et
al
.
[5
3
]
Ea
st
er
n
A
fr
ic
a
C
ro
ss
-s
ec
ti
o
n
al
-
1
1
8
2
5
6
5
Fi
rs
t
A
N
C
to
ap
p
ro
xi
m
at
el
y
9
m
o
n
th
s
p
o
st
p
ar
tu
m
.
In
fo
rm
at
io
n
o
n
ge
st
at
io
n
al
ag
e
at
fi
rs
tA
N
C
is
n
o
tp
ro
vi
d
ed
.A
ll
w
o
m
en
in
th
is
st
u
d
y
h
ad
an
H
IV
te
st
at
ap
p
ro
xi
m
at
el
y
9
m
o
n
th
s
p
o
st
p
ar
tu
m
-
-
N
o
N
o
K
in
u
th
ia
et
al
.
[3
6
]
Ea
st
er
n
A
fr
ic
a
C
ro
ss
-s
ec
ti
o
n
al
-
5
3
7
7
9
Fi
rs
t
A
N
C
to
ap
p
ro
xi
m
at
el
y
6
w
ee
ks
p
o
st
p
ar
tu
m
.
In
fo
rm
at
io
n
o
n
ge
st
at
io
n
al
ag
e
at
fi
rs
tA
N
C
is
n
o
tp
ro
vi
d
ed
.A
ll
w
o
m
en
in
th
is
st
u
d
y
h
ad
an
H
IV
te
st
ap
p
ro
xi
m
at
el
y
6
w
ee
ks
p
o
st
p
ar
tu
m
-
-
N
o
N
o
K
in
u
th
ia
et
al
.
[3
7
]
Ea
st
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
2
0
1
1
–2
0
1
3
2
5
1
2
7
8
D
at
e
o
f
fi
rs
t
A
N
C
vi
si
t
to
d
at
e
o
f
d
el
iv
er
y.
M
ed
ia
n
ge
st
at
io
n
al
at
fi
rs
t
A
N
C
w
as
2
7
w
ee
ks
D
at
e
o
f
d
el
iv
er
y
to
9
m
o
n
th
s
p
o
st
p
ar
tu
m
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
n
o
t
p
ro
vi
d
ed
.
N
in
et
y-
ei
gh
t
p
er
ce
n
t
o
f
p
ar
ti
ci
p
an
ts
w
er
e
re
ta
in
ed
th
ro
u
gh
9
m
o
n
th
s
p
o
st
p
ar
tu
m
-
-
N
o
N
o
T
ab
le
1
(c
o
n
ti
n
u
ed
)
C
o
n
tr
as
t
es
ti
m
at
ed
b
y
th
e
IR
R
o
r
h
az
ar
d
ra
ti
o
P
u
b
li
ca
ti
o
n
R
eg
io
n
St
u
d
y
d
es
ig
n
St
u
d
y
ye
ar
s
In
ci
d
en
t
ca
se
s
o
f
H
IV
P
er
so
n
-
ye
ar
s
D
efi
n
it
io
n
o
f
p
re
gn
an
cy
D
efi
n
it
io
n
o
f
b
re
as
t-
fe
ed
in
g
Ex
p
o
se
d
gr
o
u
p
vs
.
U
n
ex
p
o
se
d
gr
o
u
p
H
ig
h
-r
is
k
p
ar
ti
ci
p
an
t
re
cr
u
it
m
en
t
P
ar
en
t
st
u
d
y
w
as
a
cl
in
ic
al
tr
ia
l
o
f
an
H
IV
p
re
ve
n
ti
o
n
in
te
rv
en
ti
o
n
M
b
iz
vo
et
al
.
[3
9
]
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
1
9
9
1
–1
9
9
5
6
6
1
3
7
5
D
at
e
o
f
fi
rs
t
A
N
C
vi
si
t
to
d
at
e
o
f
d
el
iv
er
y.
In
fo
rm
at
io
n
o
n
ge
st
at
io
n
al
ag
e
at
fi
rs
t
A
N
C
is
n
o
t
p
ro
vi
d
ed
D
at
e
o
f
d
el
iv
er
y
to
2
4
m
o
n
th
s
p
o
st
p
ar
tu
m
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
n
o
t
p
ro
vi
d
ed
-
-
N
o
N
o
M
ep
h
am
et
al
.
[5
2
]
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
2
0
0
1
–2
0
0
5
3
8
7
1
7
Fi
rs
t
A
N
C
to
ap
p
ro
xi
m
at
el
y
6
m
o
n
th
s
p
o
st
p
ar
tu
m
.
M
ed
ia
n
ge
st
at
io
n
al
ag
e
at
fi
rs
t
A
N
C
w
as
2
5
w
ee
ks
.
A
ll
w
o
m
en
in
th
is
st
u
d
y
h
ad
an
H
IV
te
st
co
n
d
u
ct
ed
at
ap
p
ro
xi
m
at
el
y
6
m
o
n
th
s
p
o
st
p
ar
tu
m
-
-
N
o
N
o
M
o
o
d
le
y
et
al
.
[4
2
]
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
2
0
0
5
–2
0
0
7
4
8
1
9
4
6
Fi
rs
t
A
N
C
to
ap
p
ro
xi
m
at
el
y
1
2
m
o
n
th
s
p
o
st
p
ar
tu
m
.
M
ed
ia
n
ge
st
at
io
n
al
ag
e
at
fi
rs
t
A
N
C
w
as
2
5
w
ee
ks
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
n
o
t
p
ro
vi
d
ed
.
Ei
gh
ty
-e
ig
h
t
p
er
ce
n
t
co
m
p
le
te
d
st
u
d
y
fo
ll
o
w
-u
p
-
-
N
o
N
o
M
o
o
d
le
y
et
al
.
[4
3
]
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
2
0
0
8
–2
0
1
0
6
1
0
9
Fi
rs
t
A
N
C
to
ap
p
ro
xi
m
at
el
y
1
4
w
ee
ks
p
o
st
p
ar
tu
m
.
M
ed
ia
n
ge
st
at
io
n
al
ag
e
at
fi
rs
t
A
N
C
w
as
2
4
w
ee
ks
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
n
o
t
p
ro
vi
d
ed
-
-
N
o
N
C
T
0
1
6
8
3
4
6
1
:
Ev
al
u
at
ed
th
e
ef
fi
ca
cy
o
f
en
h
an
ce
d
H
IV
co
u
n
se
li
n
g
d
u
ri
n
g
an
te
n
at
al
an
d
p
o
st
n
at
al
p
er
io
d
s
o
n
in
ci
d
en
ce
o
f
ST
Is
an
d
ri
sk
-t
ak
in
g
b
eh
av
io
r
M
u
n
jo
m
a
et
al
.
[4
4
]
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
2
0
0
2
–2
0
0
8
1
7
2
9
8
Fi
rs
t
A
N
C
to
ap
p
ro
xi
m
at
el
y
9
m
o
n
th
s
p
o
st
p
ar
tu
m
.
In
fo
rm
at
io
n
o
n
ge
st
at
io
n
al
ag
e
at
fi
rs
t
A
N
C
is
n
o
t
p
ro
vi
d
ed
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
3
8
.2
m
o
n
th
s;
st
ra
ti
fi
ed
es
ti
m
at
es
en
ab
le
d
th
e
as
ce
rt
ai
n
m
en
t
o
f
in
ci
d
en
ce
b
et
w
ee
n
fi
rs
t
A
N
C
an
d
9
m
o
n
th
s
o
n
ly
-
-
N
o
N
o
N
ik
u
ze
et
al
.
[4
5
]
Ea
st
er
n
A
fr
ic
a
C
ro
ss
-s
ec
ti
o
n
al
2
0
1
6
3
3
8
0
5
N
o
t
cl
ea
rl
y
d
efi
n
ed
,
b
u
t
th
e
la
st
H
IV
te
st
o
cc
u
rr
ed
ap
p
ro
xi
m
at
el
y
9
m
o
n
th
s
p
o
st
p
ar
tu
m
-
-
N
o
N
o
T
ah
a
et
al
.[
4
8
]
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
1
9
9
0
–1
9
9
5
9
7
2
3
0
2
Fi
rs
t
A
N
C
vi
si
t
to
6
ye
ar
s
p
o
st
p
ar
tu
m
.
A
ve
ra
ge
le
n
gt
h
o
f
fo
ll
o
w
-u
p
w
as
3
0
.2
m
o
n
th
s.
St
ra
ti
fi
ed
re
su
lt
s
ar
e
n
o
t
p
ro
vi
d
ed
-
-
N
o
N
o
T
h
o
m
so
n
et
al
.
[5
4
]b
So
u
th
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
2
0
0
4
–2
0
1
3
2
4
4
4
7
LM
P
to
en
d
o
f
p
re
gn
an
cy
V
ar
ia
b
le
b
as
ed
o
n
p
re
gn
an
cy
o
u
tc
o
m
e:
P
re
gn
an
cy
lo
ss
at
<
6
w
ee
ks
ge
st
at
io
n
:
N
/
A
.
P
re
gn
an
cy
lo
ss
b
et
w
ee
n
6
an
d
2
0
w
ee
ks
ge
st
at
io
n
:
fi
rs
t
2
8
d
ay
s
fo
ll
o
w
in
g
p
re
gn
an
cy
lo
ss
P
re
gn
an
cy
lo
ss
2
0
w
ee
ks
ge
st
at
io
n
o
r
in
fa
n
t
d
ea
th
b
ef
o
re
6
m
o
n
th
s
o
f
ag
e:
fi
rs
t
4
2
d
ay
s
fo
ll
o
w
in
g
p
re
gn
an
cy
/i
n
fa
n
t
lo
ss
L
iv
e
b
ir
th
an
d
n
o
in
fa
n
t
d
ea
th
b
ef
o
re
6
m
o
n
th
s
o
f
ag
e:
d
el
iv
er
y
to
6
m
o
n
th
s
p
o
st
p
ar
tu
m
-
-
R
ec
ru
it
ed
H
IV
se
ro
-
d
is
co
rd
an
t
co
u
p
le
s
o
n
ly
N
C
T
0
0
1
9
4
5
1
9
:
Ev
al
u
at
ed
th
e
ef
fi
ca
cy
o
f
tw
ic
e
d
ai
ly
ac
yc
lo
vi
r
o
n
H
IV
in
ci
d
en
ce
N
C
T
0
0
5
5
7
2
4
5
:
Ev
al
u
at
in
g
th
e
ef
fi
ca
cy
o
f
P
rE
P
fo
r
H
IV
p
re
ve
n
ti
o
n
T
ab
le
1
(c
o
n
ti
n
u
ed
)
C
o
n
tr
as
t
es
ti
m
at
ed
b
y
th
e
IR
R
o
r
h
az
ar
d
ra
ti
o
P
u
b
li
ca
ti
o
n
R
eg
io
n
St
u
d
y
d
es
ig
n
St
u
d
y
ye
ar
s
In
ci
d
en
t
ca
se
s
o
f
H
IV
P
er
so
n
-
ye
ar
s
D
efi
n
it
io
n
o
f
p
re
gn
an
cy
D
efi
n
it
io
n
o
f
b
re
as
t-
fe
ed
in
g
Ex
p
o
se
d
gr
o
u
p
vs
.
U
n
ex
p
o
se
d
gr
o
u
p
H
ig
h
-r
is
k
p
ar
ti
ci
p
an
t
re
cr
u
it
m
en
t
P
ar
en
t
st
u
d
y
w
as
a
cl
in
ic
al
tr
ia
l
o
f
an
H
IV
p
re
ve
n
ti
o
n
in
te
rv
en
ti
o
n
St
u
d
ie
s
th
at
co
n
tr
ib
u
te
d
es
ti
m
at
es
o
f
th
e
in
ci
d
en
ce
ra
te
d
u
ri
n
g
p
re
gn
an
cy
an
d
/o
r
b
re
as
t-
fe
ed
in
g,
an
d
es
ti
m
at
es
o
f
th
e
IR
R
o
r
h
az
ar
d
ra
ti
o
B
ra
u
n
st
ei
n
et
al
.
[5
7
]
Ea
st
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
2
0
0
6
–2
0
0
8
1
7
6
2
5
N
o
t
cl
ea
rl
y
d
efi
n
ed
.
N
o
tm
ea
su
re
d
o
ve
r
fo
ll
o
w
-
u
p
.
St
u
d
y
as
ce
rt
ai
n
ed
b
re
as
t-
fe
ed
in
g
st
at
u
s
at
b
as
el
in
e,
b
u
t
d
id
n
o
t
ap
p
ea
r
to
m
ea
su
re
ch
an
ge
s
to
th
is
st
at
u
s
o
ve
r
fo
ll
o
w
-u
p
In
ci
d
en
ce
d
u
ri
n
g
p
re
gn
an
t
P
er
io
d
vs
.
In
ci
d
en
ce
d
u
ri
n
g
n
o
n
p
re
gn
an
t
p
er
io
d
s
R
ec
ru
it
ed
FS
W
s
o
n
ly
N
o
C
h
et
ty
et
al
.
[5
5
]
So
u
th
er
n
A
fr
ic
a
N
es
te
d
su
rv
ei
ll
an
ce
st
u
d
y
2
0
1
0
–2
0
1
5
6
6
1
8
5
7
V
ar
ia
b
le
b
as
ed
o
n
p
re
gn
an
cy
o
u
tc
o
m
e:
P
re
gn
an
ci
es
en
d
in
g
in
a
st
il
l
o
r
li
ve
b
ir
th
:
th
e
p
er
io
d
b
et
w
ee
n
LM
P
an
d
d
at
e
o
f
d
el
iv
er
y
P
re
gn
an
ci
es
en
d
in
g
in
a
m
is
ca
rr
ia
ge
o
r
te
rm
in
at
io
n
:
th
e
p
er
io
d
b
et
w
ee
n
LP
M
to
d
at
e
o
f
ex
p
ec
te
d
d
el
iv
er
y
D
el
iv
er
y
to
2
m
o
n
th
s
p
o
st
p
ar
tu
m
In
ci
d
en
ce
d
u
ri
n
g
p
re
gn
an
t
p
er
io
d
.
In
ci
d
en
ce
d
u
ri
n
g
b
re
as
t-
fe
ed
in
g
p
er
io
d
vs
.
vs
.
In
ci
d
en
ce
d
u
ri
n
g
n
o
n
p
re
gn
an
t,
n
o
n
-b
re
as
t-
fe
ed
in
g
p
er
io
d
s.
In
ci
d
en
ce
d
u
ri
n
g
n
o
n
p
re
gn
an
t,
n
o
n
-
b
re
as
t-
fe
ed
in
g
p
er
io
d
s
N
o
N
o
G
ra
y
et
al
.
[5
8
]
a
Ea
st
er
n
A
fr
ic
a
P
ro
sp
ec
ti
ve
co
h
o
rt
1
9
9
4
–1
9
9
9
6
3
4
0
4
0
T
h
e
p
er
io
d
b
et
w
ee
n
p
re
gn
an
cy
id
en
ti
fi
ca
ti
o
n
an
d
th
e
im
m
ed
ia
te
p
o
st
p
ar
tu
m
p
er
io
d
.
A
ve
ra
ge
ti
m
e
b
et
w
ee
n
p
re
gn
an
cy
id
en
ti
fi
ca
ti
o
n
an
d
d
el
iv
er
y
w
as
4
.6
m
o
n
th
s
D
at
e
o
f
fi
rs
t
H
IV
te
st
in
th
e
p
o
st
p
ar
tu
m
p
er
io
d
to
d
at
e
o
f
re
p
ea
t
H
IV
te
st
.
A
ve
ra
ge
ti
m
e
b
et
w
ee
n
H
IV
te
st
s
d
u
ri
n
g
b
re
as
t-
fe
ed
in
g
w
as
1
.0
5
ye
ar
s
In
ci
d
en
ce
am
o
n
g
p
re
gn
an
t
p
er
io
d
s.
In
ci
d
en
ce
am
o
n
g
b
re
as
t-
fe
ed
in
g
p
er
io
d
s
vs
.
vs
.
In
ci
d
en
ce
am
o
n
g
n
o
n
p
re
gn
an
t,
n
o
n
-b
re
as
t-
fe
ed
in
g
p
er
io
d
s.
In
ci
d
en
ce
am
o
n
g
n
o
n
p
re
gn
an
t,
n
o
n
-b
re
as
t-
fe
ed
in
g
p
er
io
d
s
T
h
is
st
u
d
y
as
ce
rt
ai
n
ed
in
fo
rm
at
io
n
o
n
m
al
e
p
ar
tn
er
H
IV
st
at
u
s
fo
r
so
m
e
w
o
m
en
an
d
p
ro
vi
d
ed
es
ti
m
at
es
o
f
th
e
in
ci
d
en
ce
ra
te
am
o
n
g
w
o
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prediction interval: 1.1–10.4), breast-feeding only
(n¼ 17, 3.1/100 person-years, 95% prediction interval:
1.0–9.5), and pregnancy and breast-feeding combined
(n¼ 5, 4.6/100 person-years, 95% prediction interval:
1.4–15.4). We, therefore, combined estimates into a
single HIV incidence rate during ‘pregnancy and breast-
feeding’ for subsequent analyses. The estimated average of
the HIV incidence rates during pregnancy and breast-
feeding was 3.6 per 100 person-years (95% prediction
interval: 1.2–11.1; Figure S1, http://links.lww.com/
QAD/B653). Our results were unchanged after exclud-
ing one study with follow-up exceeding 24 months
postpartum [48]. There was no visual or statistical
evidence of funnel plot asymmetry (P¼ 0.3). Cochrane’s
Q statistic indicated evidence of heterogeneity
(P< 0.001), which was consistent with the wide 95%
prediction interval.
The average HIV incidence rate among pregnant and
breast-feeding women was associated with age, calendar
time, study design, and method of estimating the timing
of HIV infection (Table 2). Average HIV incidence rates
were lower among women at least 30 years old than
among women less than 20 years old (ratio of average
incidence rates: 0.5, 95% CI: 0.3–0.7), and this inverse
relationship was robust to different categorizations of
age (Table S3, http://links.lww.com/QAD/B659). HIV
incidence appeared to have an inverted u-shaped
association with calendar time (Figure S2, http://
links.lww.com/QAD/B654). After adjusting for region
and length of study, the average incidence rate for studies
conducted after 2014 was 0.4 times the average rate for
studies conducted prior to 2010 (95% CI: 0.2–0.7).
Incidence was also associated with study design. Average
rates were the highest among cross-sectional studies (4.7/
100 person-years, 95% prediction interval: 1.6–13.5),
followed by prospective cohort studies (3.4/100 person-
years, 95% prediction interval: 1.2–9.4) and surveillance
studies (2.2/100 person-years, 95% prediction interval:
0.6–7.4). Studies that defined the date of seroconversion
as the date of the first positive HIV test observed higher
incidence rates than studies that used a date between the
last negative and first positive HIV test (ratio of average
incidence rates: 4.3, 95% CI: 1.4–13.2).
After stratifying by type of high-risk population, we
observed higher estimated incidence rates among pregnant
and breast-feeding women with known HIV-positive
partners than rates estimated in a more general study
population (ratio of average incidence rates: 4.7, 95% CI:
2.2–10.2; Table S4, http://links.lww.com/QAD/B660).
Pregnancy and HIV acquisition
Ten studies contributed estimates of the association
between pregnancy and HIV acquisition. In four,
nonpregnant, non-breast-feeding periods served as the
referent [55,56,58,59]; in six, nonpregnant periods
(which included breast-feeding) were defined as thereferent [57,60–64]. There were variability definitions of
‘nonpregnant’ and ‘nonpregnant/non-breast-feeding’
because of heterogeneous definitions of pregnancy and
breast-feeding (Table 1). All studies used methods that
allowed women to contribute person-time to both
exposed and unexposed periods.
The average hazard ratio estimating the association
between pregnancy and risk of HIV acquisition was 0.9
(95% prediction interval: 0.2–3.8; Figure S3, http://
links.lww.com/QAD/B655). Although we observed
statistical evidence of funnel plot asymmetry
(P¼ 0.05), results were largely unchanged after using a
trim-and-fill analysis to impute one possibly missing
result (average hazard ratio: 1.0, 95% prediction interval:
0.3–3.3). We also observed evidence of heterogeneity
among study-specific estimates of the association
(P< 0.001), which was consistent with the wide 95%
prediction interval spanning the null. Stratified analyses
and meta-regression revealed limited evidence of
associations between the average hazard ratios and the
measured characteristics of contributing studies (Table 3).
Two estimates were generated by studies with partially
overlapping cohorts [61,64]; exclusion of either did not
change these results substantially (Tables S5, http://
links.lww.com/QAD/B661 and S6, http://links.lww.
com/QAD/B662).
Breast-feeding and HIV acquisition
Four studies compared the risk of HIVacquisition during
breast-feeding to risk during nonpregnant and non-
breast-feeding periods. The average hazard ratio estimat-
ing the association between breast-feeding and risk of
HIV acquisition was 1.0 (95% prediction interval: 0.6–
1.6; Figure S4, http://links.lww.com/QAD/B656). We
did not observe statistical evidence of funnel plot
asymmetry (P¼ 0.2). Compared with estimates of the
association between pregnancy and risk of HIV acquisi-
tion, estimates of the association between breast-feeding
and risk of HIV acquisition were more tightly clustered
around the null. We observed little evidence of
heterogeneity between the study-specific hazard ratio
estimates (P¼ 0.6), and our analyses revealed limited
evidence of associations between the average hazard ratios
and the measured characteristics of contributing studies
(Table 4).Discussion
In this meta-analysis update – which included 15 new
studies and over 77 000 additional person-years of follow-
up – the estimated average HIV incidence rate among
pregnant and breast-feeding women was above the
‘substantial risk’ threshold described by the WHO [3],
whereas the estimated average associations between
pregnancy and risk of HIV acquisition, and breast-
feeding and risk of HIVacquisition, were close to the null.
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Table 3. Stratified analysis and meta-regression of the association between pregnancy and risk of HIV acquisition.
Variable
Stratum-specific estimates Univariate meta-regression results
Number of
estimates
Pooled
HR (95% PI)
Ratio of the
pooled HR (95% CI) P value
Omnibus
P value
Region of Africa
Southern Africa 4 0.8 (0.2–3.9) 1.0 – – –
Eastern Africa 3 0.9 (0.2–4.8) 1.1 (0.3–3.7) 0.9 –
Southeastern Africa 3 0.9 (0.2–4.5) 1.1 (0.4–3.3) 0.9 1.0
High-risk cohort
No 7 0.9 (0.2–3.5) 1.0 – – –
Yes 3 0.8 (0.2–3.8) 0.9 (0.3–2.6) 0.8 0.8
Participants enrolled in an HIV-prevention clinical trial
No 6 0.7 (0.2–2.5) 1.0 – – –
Yes 4 1.2 (0.3–4.4) 1.7 (0.7–3.9) 0.2 0.2
Study design
Prospective cohort study 8 1.1 (0.3–3.4) 1.0 – – –
Nested surveillance study 2 0.6 (0.2–2.3) 0.6 (0.2–1.5) 0.2 0.2
Use of HIV RNA/DNA PCR in HIV testing algorithm
No 5 1.1 (0.3–4.4) 1.0 – – –
Yes 3 0.9 (0.2–3.8) 0.8 (0.3–2.3) 0.7 0.7
Undefined 2 – – – – – –
Estimated timing of HIV seroconversion
Date between last negative and first positive HIV test 5 1.0 (0.3–3.3) 1.0 – – –
Date of the first positive HIV test 3 1.0 (0.3–3.7) 1.1 (0.4–2.7) 0.9 0.9
Undefined 2 – – – – – –
Referent group
Not pregnant 6 0.8 (0.2–3.3) 1.0 – – –
Not pregnant or breast-feeding 4 1.0 (0.2–4.4) 1.2 (0.5–3.1) 0.7 0.7
Adjustment for confounders
Yes 8 0.8 (0.2–2.8) 1.0 – – –
No 2 1.3 (0.3–5.8) 1.6 (0.6–4.6) 0.4 0.4
Adjusted for time-varying measures of condom use
and intercourse frequencya
No 5 0.7 (0.2–2.8) 1.0 - - -
Yes 3 1.0 (0.2–4.1) 1.3 (0.5–3.7) 0.6 0.6
CI, confidence interval; HR, hazard ratio; PI, prediction interval.
aOnly among studies that used adjusted models.Prediction intervals around each of our summary
estimates were wide, highlighting the variability of
HIV incidence across populations of pregnant and
breast-feeding women in SSA.
Our results were consistent with findings from a previous
meta-analysis that reported high average HIV incidence
during pregnancy and breast-feeding [2]. Hormonal
changes during pregnancy may increase susceptibility to
HIV through changes in the vaginal epithelial thickness,
microbiome, and CCR5 coreceptor expression [65,66].
Pregnancy activates the innate immune system, increasing
inflammation and concentration of dendritic cells in the
female genital tract, while suppressing the adaptive
immune response [67,68]. Such immunologic changes
may increase risk of HIVacquisition [69–71], and can last
for several months postpartum [72,73]. Behavioral
changes occurring during pregnancy may also influence
risk of HIV acquisition. Couples may be more likely to
engage in unprotected sex during pregnancy [34,58,74],
and male partners may be more likely to seek extra-
partnership sexual liaisons during extended periods of
pregnancy-related or breast-feeding-related abstinence
[34,75–77].Substantial heterogeneity of the incidence rates, however,
cautions us from interpreting the average HIV incidence
rate estimated in this study as the incidence rate among
pregnant and breast-feeding women in SSA. Our results
suggest maternal HIV incidence rates may lower among
older compared with younger pregnant and breast-
feeding women, and higher among women in HIV
serodiscordant relationships. Additionally, we observed
changes in average HIV incidence over calendar time that
follow temporal trends observed in the region since the
1980s: a steady rise in HIV incidence until the early 2000s
[78], largely driven by increasing HIV prevalence without
viral suppression [79], followed by a slow decline that may
be attributed to expanded HIV testing and counseling,
medical male circumcision, and ART services. Inverted
u-shaped trends in HIV incidence over time have been
observed in large population-based cohorts in SSA [10–
12], with reported associations between HIV incidence
and community-level coverage of ARTand medical male
circumcision. Models predict that integrated behavioral
and biomedical interventions will reduce HIV incidence
generally [80,81], and among pregnant women specifi-
cally [82], and two cluster randomized trials of
combination HIV prevention with universal ART
Table 4. Stratified analysis and meta-regression of the association between breast-feeding and risk of HIV acquisition.
Stratum-specific estimatesb Univariate meta-regression resultsc
Variablea
Number of
estimates
Pooled
HR (95% PI)
Ratio of the
pooled HR (95% CI) P value
Omnibus
P value
Region of Africa
Southeastern Africa 2 0.9 (0.8–1.0) – – – –
Eastern Africa 1 1.1 NA NA NA NA NA
Southern Africa 1 1.2 NA NA NA NA NA
Study design
Prospective cohort 2 1.1 (0.9–1.5) – – – –
Surveillance study 2 0.9 (0.8–1.0) 0.8 (0.6–1.1) 0.2 0.2
Estimated timing of HIV seroconversion
Date between last negative and first positive HIV test 3 1.0 (0.9–1.1) – – – –
Date of the first positive HIV test 1 1.1 NA NA NA NA NA
CI, confidence interval; HR, hazard ratio; PI, prediction interval.
aThere was limited variability in the population and methodological features of included studies. All estimates were adjusted for confounders and
generated by studies that used ‘not pregnant, not breast-feeding’ as the referent group. No estimates were generated among a high-risk population
or among a population enrolled in an HIV-prevention clinical trial. Only prospective cohort studies adjusted for time-varying sexual behaviors.
b95% PI computed only when the number of estimates in the strata exceeds 1.
cMeta-regression computed only when the number of estimates exceeded 1 in both the comparison group and the referent stratum.demonstrated some reductions in community-wide HIV
incidence [83,84]. Although we expect that HIV-
negative pregnant and breast-feeding women may serve
as beneficiaries of expanded combination HIV preven-
tion, impact will likely vary across sub-groups.
Prediction intervals around estimates of the average
association between pregnancy and risk of HIV acquisi-
tion and between breast-feeding and risk of HIV
acquisition, were wide with lower and upper bounds
on either side of the null. This variability is not
unexpected; pregnancy and breast-feeding are periods
marked by significant biological and behavioral changes
that may have different effects on risk of HIV. For
example, the potential increased risk of HIVarising from
the pregnancy-induced physiological changes described
earlier may be offset by a reduction in sexual intercourse
that frequently occurs during late pregnancy and early
breast-feeding [34,54,58,74]. The direction of the
observed association between pregnancy or breast-
feeding and risk of HIV acquisition may, therefore,
depend on both study context and analytical decisions
regarding covariate measurement and adjustment [85].
Furthermore, as the physiological and behavioral changes
that accompany pregnancy and breast-feeding are
dynamic, decisions regarding how to define pregnancy,
breast-feeding, and the referent state may influence the
direction of the observed association. For example, the
inclusion of breast-feeding in the referent group may
produce estimates closer to the null as incidence rates
during breast-feeding appear similar to those during
pregnancy, whereas single categories for pregnancy and
breast-feeding may obscure periods during pregnancy or
breast-feeding when risk is truly elevated or suppressed.
Work by Thomson et al. [54] suggests that physiological
changes during pregnancy increase susceptibility to HIV,
particularly in late pregnancy and early breast-feeding.
However, additional work is needed to better understandthe interaction between biological susceptibility and
behavioral changes on risk of HIV acquisition among
pregnant and breast-feeding women in different SSA
contexts.
Our results should be interpreted in light of possible
limitations. It is unclear if contributing studies enrolled
representative cohorts of women, so the extent to which
our estimates generalize to all pregnant and breast-feeding
women in SSA is unknown. It is possible that investigators
targeted clinics in areas of elevated HIV incidence, which
may bias estimates of incidence upwards. Few estimates of
the incidence rate captured the first trimester of pregnancy,
and given the variability of risk over the course of
pregnancy [54,58,62], this may bias estimates of incidence.
The directionality of this bias is unclear; two studies report
higher incidence during early compared with late
pregnancy [58,62], whereas one reports the reverse [54].
For this reason, misclassification of early or late pregnancy-
exposed periods as nonpregnant person-time may also bias
estimates of the association in unknown directions. Finally,
our analyses were restricted by the number of studies and
the information provided by each study. The small number
of estimates may have limited our power to detect
associations between estimates and underlying sources of
heterogeneity. Differences in populations and methodo-
logical features of contributing studies may not have been
adequately captured by variables used in meta-regression
models, and several important population features were
unmeasured by contributing studies.
Although many countries in SSA have placed consider-
able focus on identifying and treating HIV-infected
pregnant and breast-feeding women, HIV-uninfected
women have received considerably less attention in
antenatal and postnatal settings. Our results support the
expansion of bio-behavioral HIV prevention interven-
tions and repeat testing throughout pregnancy and breast-
feeding towomen at high risk of HIVacquisition. Further
work is needed to identify risk factors for HIVacquisition
during pregnancy and breast-feeding to facilitate targeted
prevention interventions in antenatal and postnatal
settings. Offering female-controlled strategies, such as
tenofovir-based oral preexposure prophylaxis, and pro-
moting couple-based prevention approaches in these
settings, are important next steps that may reduce the risk
of HIV-related maternal morbidity and mortality, and
ensure continued progress towards the elimination of
mother-to-child transmission of HIV.Acknowledgements
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